Compare GFR & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GFR | DRUG |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 802.7M | 778.4M |
| IPO Year | 2023 | 2020 |
| Metric | GFR | DRUG |
|---|---|---|
| Price | $6.16 | $71.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $129.25 |
| AVG Volume (30 Days) | ★ 573.1K | 136.7K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.15 | $38.00 |
| 52 Week High | $7.16 | $123.75 |
| Indicator | GFR | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 41.01 |
| Support Level | $5.56 | $70.87 |
| Resistance Level | $6.15 | $77.16 |
| Average True Range (ATR) | 0.29 | 3.60 |
| MACD | -0.06 | -1.13 |
| Stochastic Oscillator | 23.48 | 5.32 |
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations. The company is actively developing its Hangingstone Facilities using SAGD, an enhanced oil recovery extraction method.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.